Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a new coronavirus in
the Coronaviridae family. The COVID-19 pandemic, caused by SARS-CoV-2, has …

ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …

Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA
for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in …

Introduction Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression
to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates …

Phytoestrogens, also known as xenoestrogens, are secondary metabolites derived from
plants that have similar structures and biological effects as human estrogens. These …

Introduction The emergence of SARS-CoV-2 triggered a global health emergency, causing>
7 million deaths thus far. Limited early knowledge spurred swift research, treatment, and …

The interaction of an antiviral drug Molnupiravir (MOL) with calf thymus DNA (CT-DNA) was
investigated using a series of biophysical techniques. A significant hyperchromism with a …

This chapter explores the critical intersection of regulatory processes and intellectual
property rights (IPR) within the context of vaccine development. With the ongoing global …

SARS-CoV-2 virus triggered a worldwide crisis, with world nations putting up massive efforts
to halt its spread. Molnupiravir (MLN) was the first oral, direct-acting antiviral drug approved …

COVID-19 is primarily known for its respiratory tract involvement, often leading to severe
pneumonia and exacerbation of underlying diseases. However, emerging evidence …